Knight Disposes of a Toddler-Sized Amount of Pediapharm Inc.
MONTREAL, Aug. 31, 2018 — This press release is being disseminated by Knight Therapeutics Inc. (“Knight”) (TSX:GUD), a specialty pharmaceutical company, as required by National Instrument 62-103 – The Early Warning System and Related Take Over Bid and Insider Reporting Issues regarding the disposition of securities of Pediapharm Inc. (“Pediapharm”). Since July 4, 2018, Knight […]
Knight Therapeutics Reports Second Quarter 2018 Results
MONTREAL, Aug. 09, 2018 — Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2018. Q2 2018 Highlights Financials Revenues were $2,238, a decrease of $242 or 10% versus prior period Net income was $4,019, an increase of $3,560 or 776% over […]
Notice of Knight Therapeutics’ Second Quarter 2018 Results Conference Call
MONTREAL, Aug. 02, 2018 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its second quarter 2018 financial results on Thursday, August 9th, 2018 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in […]
Knight Therapeutics and TherapeuticsMD Announce Strategic Partnership
-Knight receives license to TX-004HR and TX-001HR and agrees to invest $20 million in TherapeuticsMD- MONTREAL and BOCA RATON, Fla., July 31, 2018 — Knight Therapeutics Inc. (TSX:GUD) (“Knight“), a Canadian specialty pharmaceutical company, and TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, today announced that they have entered into a licensing agreement that grants […]
Knight Receives Adverse Notice of Reassessment from CRA
MONTREAL, July 06, 2018 — Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has received a notice of reassessment (“CRA Notice”) from the Canada Revenue Agency (“CRA”) for its fiscal year ended December 31, 2014. The CRA Notice relates to the disposition of the Priority Review Voucher (“PRV”) […]
Knight to Present at the Jefferies Global Healthcare Conference in New York City
MONTREAL, June 05, 2018 — Knight Therapeutics Inc. (TSX:GUD), a leading Canadian specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Financial Officer, is scheduled to present a corporate update at Jefferies Global Healthcare Conference on Thursday, June 7, 2018 at 4:30 pm ET in New York City. A copy of the presentation […]
Knight to Present at the National Bank Financial Quebec Conference in Toronto
MONTREAL, May 25, 2018 — Knight Therapeutics Inc. (TSX:GUD), a leading Canadian specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Financial Officer, is scheduled to present a corporate update at the National Bank Financial 8th Annual Quebec Conference on Wednesday, May 30, 2018 at 1:30 pm ET at Shangri-La Hotel in Toronto. […]
Knight Reports First Quarter 2018 Results
MONTREAL, May 10, 2018 — Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2018. All dollar amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q1 2018 Highlights Financials Revenues were $3,154, […]
Knight Therapeutics Inc. announces voting results from the Annual Meeting
MONTREAL, May 09, 2018 — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Corporation”) announced today the voting results from the Annual Meeting of the Shareholders held in Montreal, Quebec (“Meeting”). Election of Directors Each director nominee listed in the Management Information Circular dated March 30, 2018 (“Circular”) was elected as Director of the Corporation at […]
Notice of Knight Therapeutics’ First Quarter 2018 Results Conference Call
MONTREAL, May 03, 2018 — Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its first quarter 2018 financial results on Thursday, May 10, 2018 prior to the market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in […]
